Interestingly, the blockade of V2R using tolvaptan in patients with rapidly progressing ADPKD has been proven to slow cyst growth, supporting the involvement of the V2R pathway in ADPKD113,114. This evidence concerns the gene AVPR2 and autosomal dominant polycystic kidney disease.